For Research Purposes Only — Not for Human Consumption
All products on this website are supplied strictly for laboratory and research purposes only. They are not medicines, foods, or supplements, and are not intended for human consumption, human or veterinary use, or to diagnose, treat, cure, or prevent any disease.
Tirzepatide
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, studied for its synergistic metabolic effects.
30mg Tirzepatide pre-filled disposable pen. Includes 10 single-use needles and 10 alcohol wipes.
Note: This is a reconstitution kit — you are responsible for measuring and preparing the product yourself.
Research Use Only: This product is supplied strictly for laboratory and research purposes and is not intended for human consumption, human or veterinary use, or to diagnose, treat, cure, or prevent any disease.
Product Information
Tirzepatide is a synthetic 39-amino-acid peptide and dual incretin receptor agonist that simultaneously activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Developed by Eli Lilly and approved as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management), it has a molecular mass of approximately 4,814 Da and an extended half-life of around five days, supporting once-weekly subcutaneous administration in clinical and research settings.
Scientific Overview
Tirzepatide (LY3437943) is a synthetic peptide engineered from the native GIP sequence, incorporating a C20 fatty acid acylation that enables albumin binding, slows enzymatic degradation and reduces renal clearance — yielding a half-life of approximately five days. Uniquely, it functions as a dual agonist at both the GIP receptor and the GLP-1 receptor, distinguishing it from single GLP-1 agonists such as semaglutide. Its molecular mass is approximately 4,814 Da and its sequence comprises 39 amino acids. GIP receptor agonism is studied for its role in glucose-dependent insulin secretion and its emerging influence on adipose tissue metabolism and bone biology. GLP-1 receptor agonism is associated with delayed gastric emptying, increased satiety signalling, reduced appetite and glucose-dependent insulin secretion. Research suggests the combined engagement of both incretin pathways may produce complementary and potentially superior metabolic effects — including greater reductions in body weight and improvements in glycaemic control — than targeting either receptor alone.
How It Works
Tirzepatide exerts its studied effects through simultaneous activation of two key incretin receptor pathways: • GIP receptor agonism — enhances glucose-dependent insulin secretion from pancreatic beta cells in response to meals and is being investigated for effects on fat metabolism and insulin sensitivity. • GLP-1 receptor agonism — delays gastric emptying, signals fullness to the brain's appetite centres and supports glucose-dependent insulin secretion, collectively reducing appetite and food intake. The dual mechanism is researched for its potential to produce greater reductions in body weight and improvements in blood glucose than single-hormone GLP-1 agonists, while maintaining a glucose-dependent insulin response that reduces the risk of hypoglycaemia.
Research & References
The information on this page is supported by peer-reviewed clinical research and published trial data.
Frequently Asked Questions
It engages two receptors (GIP and GLP-1), which research suggests may produce complementary metabolic effects and greater weight reduction than targeting GLP-1 alone.
Variant Comparison
Compare the available formats side-by-side to find the right option for your research needs.
| Compare | Selected 30mg Disposable Pen £80 | 40mg Disposable Pen £100 | 60mg Disposable Pen £130 | Tirzepatide Vial Kit £70 |
|---|---|---|---|---|
| Format | — | — | — | — |
| Total Retatrutide | — | — | — | — |
| Price per mg | — | — | — | — |
| Single-use needles | — | — | — | — |
| Alcohol wipes | — | — | — | — |
| Bacteriostatic water | 3ml | |||
| Pre-mixed & ready | ||||
| Self-measurement required |
Peptide Comparison
See how Tirzepatide compares to related peptides in the same category.
| Compare | Selected Tirzepatide £159.00 |  Retatrutide £189.00 |
|---|---|---|
| What it does | A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, studied for its synergistic metabolic effects. | A triple receptor agonist of GLP-1, GIP and glucagon studied for its role in metabolic and weight management research. |
| Category | GLP-1 | GLP-1 |
| Molecular mass | ≈4814 Da | ≈4731 Da |
| Purity | ≥99% | ≥99% |
| Sequence length | 39 aa | 39 aa |
Knowledge Articles
Related Products
For Research Purposes Only — Not for Human Consumption
All products on this website are supplied strictly for laboratory and research purposes only. They are not medicines, foods, or supplements, and are not intended for human consumption, human or veterinary use, or to diagnose, treat, cure, or prevent any disease.